drugset
drugset / Trial / NCT05523596

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

NCT05523596 ↗

Phase 1 Completed 13 enrolled IC-MedTech Corporation
Non-randomizedSequentialOpen-labelOther

Summary

A Phase 1 Non-Randomized Open Label Study of Oral ICM20

Timeline

Start
2023-08-20
Primary completion
2025-10-03
Completion
2025-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Benznidazole Small molecule — —
Subject ICM20 Small molecule — Oral

Indications

No indication recorded.